Get access

Digoxin for preventing or treating neonatal respiratory distress syndrome

  • Review
  • Intervention

Authors

  • Roger Soll,

    Corresponding author
    1. University of Vermont, Division of Neonatal-Perinatal Medicine, Burlington, Vermont, USA
    • Roger Soll, Division of Neonatal-Perinatal Medicine, University of Vermont, Fletcher Allen Health Care, Smith 552A, 111 Colchester Avenue, Burlington, Vermont, 05401, USA. Roger.Soll@vtmednet.org.

    Search for more papers by this author
  • Eren Özek

    1. Maramara University Medical Center, Pediatrics / Division of Neonatology, Istanbul, Turkey
    Search for more papers by this author

Abstract

Background

Lendrum 1955 suggested that pulmonary edema secondary to congestive heart failure may contribute to neonatal respiratory distress syndrome (RDS). Based on this hypothesis, investigators began to use digitalis glycosides to improve myocardial contractility and decrease congestive heart failure. The first use of digitalis glycosides in infants with RDS was reported by Stahlman 1959. Stahlman reported a reduction in mortality in an uncontrolled trial of digitalis in infants with RDS.

Objectives

To assess the effect of digoxin on mortality in premature infants at risk for or with RDS.

Search methods

Searches were made of the Oxford Database of Perinatal Trials, Medline (MeSH terms: digoxin; limits: age groups, newborn infants; publication type, clinical trial), previous reviews including cross references, abstracts, conference and symposia proceedings, expert informants, and journal handsearching in the English language.

When updated in December 2008, the search was expanded to include Medline, CINHAL, and Embase (MeSH terms and text words: digoxin or digitalis; limits: age group, all infants; publication type: clinical trial).

Selection criteria

Randomized and quazi-randomized controlled trials of digoxin in either the prevention or treatment of RDS are included in this overview.

Data collection and analysis

Data regarding clinical outcomes were excerpted from the trial reports by one review author (RS) and checked by the second review author (EO). Data were analyzed according to the standards of the Cochrane Neonatal Review Group.

Main results

Two randomized controlled trials have studied the effects of digoxin in the prevention and treatment of RDS. No improvement in respiratory status or mortality was noted. Meta-analysis of the effect of digoxin given to infants at risk of or with RDS on mortality does not suggest any benefit of digoxin treatment (typical relative risk 1.27 95% CI 0.78 to 2.07; typical risk difference 0.06, 95% CI -0.06 to 0.17).

Authors' conclusions

Although hemodynamic disturbances play a role in the overall pathogenesis of respiratory distress syndrome, the specific contribution of early congestive heart failure (unrelated to hemodynamically significant patent ductus arteriosus) does not appear to be a significant factor in RDS. Treatment with digoxin has no proven value in infants solely affected with RDS.

Plain language summary

Digoxin for preventing or treating neonatal respiratory distress syndrome

There is no evidence that the administration of digoxin helps babies with neonatal respiratory distress syndrome.
Sometimes a newborn baby has lungs that are not expanded properly. This is most common in preterm babies (born before 34 weeks) and is known as respiratory distress syndrome (RDS). Congestive heart failure may lead to fluid accumulation in the lungs, contributing to RDS. The drug digoxin has been used for congestive heart failure and has been suggested for RDS. The review found no evidence from trials that digoxin reduces congestive heart failure, prevents RDS or improves the outcome of preterm babies with RDS.

Ringkasan bahasa mudah

Digoxin untuk mencegah atau merawat `respiratory distress syndrome' neonat

Tidak ada bukti bahawa memberi ubat digoxin dapat membantu bayi yang mengalami `neonatal respiratory distress syndrome'.
Kadang-kadang bayi yang baru lahir mempunyai paru-paru yang tidak berkembang dengan baik. Masalah ini biasa berlaku dalam kalangan bayi pramatang (lahir sebelum 34 minggu) dan dikenali sebagai respiratory distress syndrome (RDS). Kegagalan jantung kongestif boleh menyebabkan pengumpulan cecair dalam paru-paru, yang menyumbang kepada RDS. Ubat digoxin telahpun digunakan untuk merawat kegagalan jantung kongestif dan dicadangkan untuk RDS. Ulasan ini tidak mendapat sebarang bukti dari sebarang kajian yang digoxin dapat mengurangkan kegagalan jantung kongestif, mencegah RDS atau meningkatkan hasil bagi bayi pramatang yang mengalami RDS.

Catatan terjemahan

Diterjemahkan oleh Foo Sook Lee (Penang Medical College) Disunting oleh Tuan Hairulnizam Tuan Kamauzaman (Universiti Sains Malaysia) Untuk sebarang pertanyaan mengenai terjemahan ini sila hubungi fslee@pmc.edu.my.

Get access to the full text of this article